Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

AIC100

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

AffyImmune Therap

Drug class:

ICAM-1-targeted CAR-T immunotherapy

‹

›

No biomarker	Thyroid Gland Carcinoma	No biomarker	Thyroid Gland Carcinoma	AIC100 Sensitive: B - Late Trials AIC100 Sensitive : B	AIC100 Sensitive: B - Late Trials AIC100 Sensitive : B
No biomarker	Thyroid Gland Anaplastic Carcinoma	No biomarker	Thyroid Gland Anaplastic Carcinoma	AIC100 Sensitive: B - Late Trials AIC100 Sensitive : B	AIC100 Sensitive: B - Late Trials AIC100 Sensitive : B
ICAM1 overexpression	Breast Cancer	ICAM1 overexpression	Breast Cancer	AIC100 Sensitive: D – Preclinical AIC100 Sensitive : D	AIC100 Sensitive: D – Preclinical AIC100 Sensitive : D
ICAM1 overexpression	Multiple Myeloma	ICAM1 overexpression	Multiple Myeloma	AIC100 Sensitive: D – Preclinical AIC100 Sensitive : D	AIC100 Sensitive: D – Preclinical AIC100 Sensitive : D
ICAM1 overexpression	Gastric Cancer	ICAM1 overexpression	Gastric Cancer	AIC100 Sensitive: D – Preclinical AIC100 Sensitive : D	AIC100 Sensitive: D – Preclinical AIC100 Sensitive : D